Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights May 11, 2022
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones May 10, 2022
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines April 14, 2022
Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer April 12, 2022
Werewolf Therapeutics and Jazz Pharmaceuticals Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule April 8, 2022
